AU2010278779B2 - Nitroimidazooxazine and nitroimidazooxazole analogues and their uses - Google Patents

Nitroimidazooxazine and nitroimidazooxazole analogues and their uses Download PDF

Info

Publication number
AU2010278779B2
AU2010278779B2 AU2010278779A AU2010278779A AU2010278779B2 AU 2010278779 B2 AU2010278779 B2 AU 2010278779B2 AU 2010278779 A AU2010278779 A AU 2010278779A AU 2010278779 A AU2010278779 A AU 2010278779A AU 2010278779 B2 AU2010278779 B2 AU 2010278779B2
Authority
AU
Australia
Prior art keywords
methyl
nitro
oxazine
imidazo
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010278779A
Other languages
English (en)
Other versions
AU2010278779A1 (en
Inventor
Adrian Blaser
William Alexander Denny
Zhenkun Ma
Andrew M. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Alliance for TB Drug Development
Original Assignee
Global Alliance for TB Drug Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Alliance for TB Drug Development filed Critical Global Alliance for TB Drug Development
Publication of AU2010278779A1 publication Critical patent/AU2010278779A1/en
Application granted granted Critical
Publication of AU2010278779B2 publication Critical patent/AU2010278779B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010278779A 2009-07-31 2010-07-30 Nitroimidazooxazine and nitroimidazooxazole analogues and their uses Ceased AU2010278779B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23042209P 2009-07-31 2009-07-31
US61/230,422 2009-07-31
PCT/US2010/043908 WO2011014776A1 (en) 2009-07-31 2010-07-30 Nitroimidazooxazine and nitroimidazooxazole analogues and their uses

Publications (2)

Publication Number Publication Date
AU2010278779A1 AU2010278779A1 (en) 2012-03-08
AU2010278779B2 true AU2010278779B2 (en) 2014-08-14

Family

ID=42829983

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010278779A Ceased AU2010278779B2 (en) 2009-07-31 2010-07-30 Nitroimidazooxazine and nitroimidazooxazole analogues and their uses

Country Status (13)

Country Link
US (1) US8293734B2 (enExample)
EP (1) EP2459570B1 (enExample)
JP (1) JP5685254B2 (enExample)
KR (1) KR101738868B1 (enExample)
CN (1) CN102741259B (enExample)
AU (1) AU2010278779B2 (enExample)
BR (1) BR112012002214B1 (enExample)
CA (1) CA2769263C (enExample)
ES (1) ES2530266T3 (enExample)
NZ (1) NZ598165A (enExample)
RU (1) RU2540860C2 (enExample)
WO (1) WO2011014776A1 (enExample)
ZA (1) ZA201201259B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
EP2697232B1 (en) 2011-04-15 2016-05-18 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo[2,1-b][1,3]oxazine bactericides
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
KR101918469B1 (ko) * 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
US10301294B2 (en) * 2013-03-13 2019-05-28 The Broad Institute Inc. Compounds for the treatment of tuberculosis
CN104059082B (zh) * 2013-03-21 2016-08-03 苏州迈泰生物技术有限公司 硝基咪唑杂环类化合物及其在制备治疗结核病药物中的应用
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
AR101704A1 (es) 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
KR101682356B1 (ko) 2014-11-04 2016-12-06 한국화학연구원 이미다조 옥사진 유도체, 이의 약학적으로 허용 가능한 염 또는 이의 광학이성질체 및 이를 유효성분으로 함유하는 약제학적 조성물
JP6542900B2 (ja) 2015-01-29 2019-07-10 メッドシャイン ディスカバリー インコーポレイテッド 抗肺結核症のニトロイミダゾール誘導体
GB201519054D0 (en) * 2015-10-28 2015-12-09 Univ Dundee Composition
WO2017146246A1 (ja) 2016-02-26 2017-08-31 大塚製薬株式会社 ピペリジン誘導体
CN108727406B (zh) 2017-03-28 2021-12-07 北京协和制药二厂 含氮杂环取代的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
EP3962903A1 (en) * 2019-05-01 2022-03-09 Boehringer Ingelheim International GmbH (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
EP4447961A1 (en) 2021-12-14 2024-10-23 Boehringer Ingelheim International GmbH Aldosterone synthase inhibitors for treating chronic kidney disease
CN114249747A (zh) * 2021-12-27 2022-03-29 苏州虞美景盛新药开发有限公司 一种用于治疗广泛耐药性结核病的硝基咪唑吡喃类药物的新合成工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001562A1 (en) * 1995-06-26 1997-01-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
EP1555267A1 (en) * 2002-10-11 2005-07-20 Otsuka Pharmaceutical Co., Ltd. 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES
WO2009120789A1 (en) * 2008-03-26 2009-10-01 Global Alliance For Tb Drug Development Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL41744A0 (en) 1972-03-16 1973-05-31 Ciba Geigy Ag New aryl ether derivatives,their production and their use as pesticides
CH568715A5 (enExample) 1972-03-16 1975-11-14 Ciba Geigy Ag
FR2575158B1 (fr) 1984-12-20 1987-10-02 Pf Medicament Arylalcoyloxymethyl-2 morpholines, leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
SU1271861A1 (ru) * 1985-05-07 1986-11-23 Иркутский институт органической химии СО АН СССР Способ получени 2,2-диметил-3-цианометилиденбензимидазо @ 2,1- @ -1,3-оксазолидина
US6087358A (en) * 1995-06-26 2000-07-11 Pathogenesis Corporation Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof
WO2005042542A1 (en) * 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
JP4789966B2 (ja) 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
JP4787529B2 (ja) 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
EP1650211B1 (en) * 2004-09-17 2011-09-14 Daiso Co., Ltd. Process for preparing imidazopyran derivatives
EP1910379B1 (en) * 2005-07-28 2011-10-19 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
RU2008129726A (ru) 2005-12-23 2010-01-27 Новартис АГ (CH) Нитроимидазольные производные
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
WO2008008480A2 (en) 2006-07-12 2008-01-17 Cumbre Pharmaceuticals Inc. Nitroheteroaryl-containing rifamycin derivatives
MY147757A (en) * 2007-03-09 2013-01-15 Sanofi Aventis Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001562A1 (en) * 1995-06-26 1997-01-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
EP1555267A1 (en) * 2002-10-11 2005-07-20 Otsuka Pharmaceutical Co., Ltd. 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES
WO2009120789A1 (en) * 2008-03-26 2009-10-01 Global Alliance For Tb Drug Development Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones

Also Published As

Publication number Publication date
BR112012002214B1 (pt) 2022-01-25
CN102741259A (zh) 2012-10-17
WO2011014776A1 (en) 2011-02-03
JP2013500997A (ja) 2013-01-10
ZA201201259B (en) 2013-08-28
KR101738868B1 (ko) 2017-05-23
RU2012107180A (ru) 2013-09-10
CA2769263C (en) 2017-03-07
ES2530266T3 (es) 2015-02-27
AU2010278779A1 (en) 2012-03-08
NZ598165A (en) 2013-05-31
CA2769263A1 (en) 2011-02-03
US8293734B2 (en) 2012-10-23
EP2459570B1 (en) 2014-12-24
EP2459570A1 (en) 2012-06-06
US20110028466A1 (en) 2011-02-03
BR112012002214A2 (pt) 2020-08-18
CN102741259B (zh) 2016-04-13
KR20120084714A (ko) 2012-07-30
JP5685254B2 (ja) 2015-03-18
RU2540860C2 (ru) 2015-02-10

Similar Documents

Publication Publication Date Title
EP2459570B1 (en) Nitroimidazooxazine analogues and their uses
AU2014221775B2 (en) TETRAHYDROIMIDAZO[1,5-d][1,4]OXAZEPINE DERIVATIVE
EP1235831B1 (en) New oxabispidine compounds useful in the treatment of cardiac arrhythmias
EP3207042B1 (en) Antibacterial basic biaromatic derivatives with aminoalkoxy substitution
AU2010278777B2 (en) Nitroimidazooxazines and their uses in anti-tubercular therapy
EP3634968B1 (en) Heterocyclic compounds useful as anti-bacterial agents and method for production thereof
CN111094267B (zh) 作为RORγ抑制剂的磺酰基取代的双环化合物
EP3458452B1 (en) Heterocyclic compounds useful as anti-bacterial agents and method for production
EP2471792B1 (en) 3-(biaryloxy) propionic acid derivative
EP2729475B1 (de) Carbonsäurederivate mit einem Oxazolo[4,5-d]Pyrimidinring
US9198913B2 (en) Nitroimidazooxazines and their uses in anti-tubercular therapy
US11161837B2 (en) Benzofuran derivatives for the treatment of hepatitis C
KR20250076657A (ko) 인간 알도스테론 합성효소(cyp11b2) 억제제

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired